AARON N SMITH
Osteopathic Medicine at Powell St, Oakland, CA
License number
California A140709
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California A140709
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
2100 Powell St SUITE 920, Oakland, CA 94608
35219 Avenue D, Yucaipa, CA 92399
35219 Avenue D, Yucaipa, CA 92399
Phone
(510) 350-2777
Personal information
See more information about AARON N SMITH at radaris.comName
Address
Phone
475 Roanoke Dr, Martinez, CA 94553
4772 Kimberley Cmn, Livermore, CA 94550
4775 Monte Vista Rd, Phelan, CA 92371
4719 W 12Th St, Los Angeles, CA 90019
47 E Ingram St, Stockton, CA 95204
Professional information
Aaron Smith - Oakland, CA
Work:
MicroMenders
Inside Sales Representative Andronico's Market - Berkeley, CA
Cashier Salesforce.com - San Francisco, CA
Junior Project Manager Intern Whole Foods Market - Oakland, CA
Cashier
Inside Sales Representative Andronico's Market - Berkeley, CA
Cashier Salesforce.com - San Francisco, CA
Junior Project Manager Intern Whole Foods Market - Oakland, CA
Cashier
Education:
City College of San Francisco
Certificate in Fundamentals of Technical Support
Certificate in Fundamentals of Technical Support
Aaron Smith - Oakland, CA
Work:
Salesforce.com
IT Workspace Expansion and Integration Year Up
Imformation technology technician Andronico's Market
Courtesy Clerk Andronico's Markets
Cashier Andronicos
Cashier Safeway Inc
Deli Associate
IT Workspace Expansion and Integration Year Up
Imformation technology technician Andronico's Market
Courtesy Clerk Andronico's Markets
Cashier Andronicos
Cashier Safeway Inc
Deli Associate
Education:
Year Up
I.T Tech City College of San Francisco
Computer Networking Information Technology
I.T Tech City College of San Francisco
Computer Networking Information Technology
Pi3 Kinase Inhibitors And Methods Of Their Use
US Patent:
2010007, Mar 25, 2010
Filed:
Feb 14, 2007
Appl. No.:
12/279148
Inventors:
Zhi-Jie Ni - Emeryville CA, US
Sabina Pecchi - Emeryville CA, US
Matthew Burger - Emeryville CA, US
Wooseok Han - Emeryvile CA, US
Aaron Smith - Emeryville CA, US
Gordana Atallah - Emeryville CA, US
Sarah Bartulis - Emeryville CA, US
Kelly Frazier - Emeryville CA, US
Joelle Verhagen - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
Ed Iwanowicz - Emeryville CA, US
Tom Hendrickson - Emeryville CA, US
Mark Knapp - Emeryville CA, US
Hanne Merritt - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Marion Wiesmann - Emeryville CA, US
Darren Mark Legrand - West Sussex, GB
Ian Bruce - West Sussex, GB
James Dale - West Sussex, GB
Jiong Lan - Emeryville CA, US
Barry Levine - Emeryville CA, US
Abran Costales - Emeryville CA, US
Jui Liu - Emeryville CA, US
Teresa Pick - Emeryville CA, US
Daniel Menezes - Emeryville CA, US
Sabina Pecchi - Emeryville CA, US
Matthew Burger - Emeryville CA, US
Wooseok Han - Emeryvile CA, US
Aaron Smith - Emeryville CA, US
Gordana Atallah - Emeryville CA, US
Sarah Bartulis - Emeryville CA, US
Kelly Frazier - Emeryville CA, US
Joelle Verhagen - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
Ed Iwanowicz - Emeryville CA, US
Tom Hendrickson - Emeryville CA, US
Mark Knapp - Emeryville CA, US
Hanne Merritt - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Marion Wiesmann - Emeryville CA, US
Darren Mark Legrand - West Sussex, GB
Ian Bruce - West Sussex, GB
James Dale - West Sussex, GB
Jiong Lan - Emeryville CA, US
Barry Levine - Emeryville CA, US
Abran Costales - Emeryville CA, US
Jui Liu - Emeryville CA, US
Teresa Pick - Emeryville CA, US
Daniel Menezes - Emeryville CA, US
International Classification:
A61K 31/5377, C07D 471/04, C07D 487/04, C07D 413/14, A61K 31/437, A61K 31/5025, A61P 35/00
US Classification:
5142358, 546121, 544236, 544121, 514300, 514248
Abstract:
Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.
Pi 3-Kinase Inhibitors And Methods Of Their Use
US Patent:
8173647, May 8, 2012
Filed:
Feb 6, 2008
Appl. No.:
12/449286
Inventors:
Gordana Atallah - Emeryville CA, US
Sarah Bartulis - Emeryville CA, US
Matthew Burger - Emeryville CA, US
Hanne Merritt - Emeryville CA, US
Simon Ng - Emeryville CA, US
Zhi-Jie Ni - Emeryville CA, US
Sabina Pecchi - Emeryville CA, US
Keith B. Pfister - Emeryville CA, US
Aaron Smith - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Allan Wagman - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
Sarah Bartulis - Emeryville CA, US
Matthew Burger - Emeryville CA, US
Hanne Merritt - Emeryville CA, US
Simon Ng - Emeryville CA, US
Zhi-Jie Ni - Emeryville CA, US
Sabina Pecchi - Emeryville CA, US
Keith B. Pfister - Emeryville CA, US
Aaron Smith - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Allan Wagman - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
International Classification:
A61K 31/5377, C07D 413/14
US Classification:
5142315, 544106, 544111, 544122, 5142312, 5142322
Abstract:
Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases.
Pyrimidine Derivatives Used As Pi-3-Kinase Inhibitors
US Patent:
8217035, Jul 10, 2012
Filed:
Jan 22, 2007
Appl. No.:
12/161537
Inventors:
Matthew Burger - Emeryville CA, US
Zhi-Jie Ni - Emeryville CA, US
Sabina Pecchi - Emeryville CA, US
Gordana Atallah - Emeryville CA, US
Sarah Bartulis - Emeryville CA, US
Kelly Frazier - Emeryville CA, US
Aaron Smith - Emeryville CA, US
Joelle Verhagen - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
Allan Wagman - Emeryville CA, US
Simon Ng - Emeryville CA, US
Keith Pfister - Emeryville CA, US
Daniel Poon - Emeryville CA, US
Alicia Louie - Emeryville CA, US
Teresa Pick - Emeryville CA, US
Paul Barsanti - Emeryville CA, US
Edwin Iwanowicz - Emeryville CA, US
Wendy Fantl - Emeryville CA, US
Thomas Hendrickson - Emeryville CA, US
Mark Knapp - Emeryville CA, US
Hanne Merritt - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Marion Wiesmann - Emeryville CA, US
Xiaohua Xin - Emeryville CA, US
Zhi-Jie Ni - Emeryville CA, US
Sabina Pecchi - Emeryville CA, US
Gordana Atallah - Emeryville CA, US
Sarah Bartulis - Emeryville CA, US
Kelly Frazier - Emeryville CA, US
Aaron Smith - Emeryville CA, US
Joelle Verhagen - Emeryville CA, US
Yanchen Zhang - Emeryville CA, US
Allan Wagman - Emeryville CA, US
Simon Ng - Emeryville CA, US
Keith Pfister - Emeryville CA, US
Daniel Poon - Emeryville CA, US
Alicia Louie - Emeryville CA, US
Teresa Pick - Emeryville CA, US
Paul Barsanti - Emeryville CA, US
Edwin Iwanowicz - Emeryville CA, US
Wendy Fantl - Emeryville CA, US
Thomas Hendrickson - Emeryville CA, US
Mark Knapp - Emeryville CA, US
Hanne Merritt - Emeryville CA, US
Charles Voliva - Emeryville CA, US
Marion Wiesmann - Emeryville CA, US
Xiaohua Xin - Emeryville CA, US
Assignee:
Novartis AG - Basel
International Classification:
A61K 31/535, C07D 413/14
US Classification:
5142322, 544122
Abstract:
Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.